Toronto — October 25, 2025 — Leads & Copy — Biotech Equities Posted Divergent Results Friday, With Canadian Microcaps Leading The Advance On Speculative Volume And Pipeline Momentum. Bright Minds Biosciences (DRUG) Jumped 52.38 Per Cent To $0.35, While Hemostemix Inc. (HEM) Rose 47.06 Per Cent To $0.25. Revive Therapeutics Ltd. (RVV), Algernon Pharmaceuticals Inc. (AGN), And Sernova Corp (SVA) Also Posted Double-Digit Gains.
On The Downside, U.S.-Listed Biotech Majors Faced Steep Declines Amid Clinical Trial Volatility And Regulatory Uncertainty. Sarepta Therapeutics Inc. (SRPT) Dropped 18.92 Per Cent To $103.45, Followed By Biohaven Ltd. (BHVN) And Janux Therapeutics Inc. (JANX), Down 16.78 And 15.34 Per Cent Respectively. KALA BIO Inc. (KALA) And Alnylam Pharmaceuticals Inc. (ALNY) Rounded Out The Losers, With ALNY Closing At $464.90.
Analysts Cited Trial Readouts, FDA Guidance, And Sector Rotation As Key Drivers Behind The Divergence In Performance.
